Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson’s disease by D. Yu. Belousov, E. V. Afanasyeva

Subjects: Get full text

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION by A. V. Rudakova

“…The objective of this review was to describe pharmacoeconomic aspects of using apixaban for stroke and other cardiovascular events prevention in patients with NVAF. …”
Get full text

Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy by Sudhir C. Sarangi, Nivendeep Kaur, Manjari Tripathi

Subjects: Get full text

VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION»

“…VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION»…”
Get full text

On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers by Andrea Carta, Claudio Conversano

Subjects: “…pharmacoeconomics…”
Get full text

Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS. by Griffiths, R, Bleecker, G, Jabs, D, Dieterich, D, Coleson, L, Winters, D, Wolitz, R, Steinberg, E

“…A decision-analytical simulation model was constructed to perform a pharmacoeconomic analysis of the following 3 treatment strategies for previously untreated cytomegalovirus (CMV) retinitis in patients with AIDS: (i) intravenous foscarnet (IVF) for induction and maintenance therapy; (ii) intravenous ganciclovir (IVG) for induction and maintenance therapy; and (iii) intravenous ganciclovir for induction therapy, followed by oral ganciclovir for maintenance therapy (IVG-ORG). …”

Pharmacoeconomic Analysis of Heartworm Preventive Compliance and Revenue in Veterinary Practices in the United States by Kennedy Mwacalimba, Deborah Amodie, Lisa Swisher, Marina Moldavchuk, Christopher Brennan, Claire Walther, Kelly Bowman

Get full text

Pharmacoeconomic analysis of adjuvant use of zonisamide therapy resistant partial epilepsy in adults by D. Yu. Belousov, E. V. Afanasyeva, E. A. Efremova

“…The purpose of pharmacoeconomic studies of the drug zonisamide is to determine it’s clinical and cost-effectiveness in adult patients with refractory partial epilepsy in comparison with other new antiepileptic drugs in the conditions of the Russian Federation. …”
Get full text

PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY by A. V. Rudakova, M. S. Berezhnova

Get full text

Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis by E A Pyadushkina, K V Gerasimova, S V Goryainov, Vitaly Vladimirovich Omelyanovsky, M V Avksentyeva, I S Krysanov

“…Objective: to make a pharmacoeconomic analysis of the use of oral (a 150-mg tablet once a month) and injectable (a solution for intravenous bolus injection of 3 mg in 3 ml once every 3 months) ibandronate in patients with postmenopausal osteoporosis (OP). …”
Get full text

Pharmacoeconomic analysis of conservative strategy for the treatment of patients with diabetic foot syndrome in Moscow by Marina Fedorovna Kalashnikova, Nadezhda Viktorovna Maksimova, Ivan Ivanovich Dedov

Subjects: Get full text

Pharmacoeconomic research of pharmacotherapy schemes of community-acquired pneumonia with the inclusion of antiviral drugs by S. O. Soloviov, V. V. Trokhymchuk, I. V. Dziublyk

Subjects: Get full text

Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis by V. R. Mkrtchyan, L. V. Brylev, O. V. Davydova, A. V. Belyanin, I. A. Shpak, A. M. Sergeev

Subjects: Get full text

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base by I. N. Dyakov, S. K. Zyryanov

“…Sensitivity analysis has been provided for validation of results. Results. Pharmacoeconomic analysis based on non-direct efficacy comparisons of iGlaLixi, Exe, Lira and Dula has shown of economic advantages of effective DM2T control. iGlaLixi has demonstrated economic advantages as well usage aGLP-1 only (direct costs decreasing vs Exe on 23,8 %, vs Dula on 15,6 %, vs Lira on 54,4 %) as their combinations with iGla 100 U (direct costs decreasing vs iGla 100 U + Exe on 23,8 %, vs iGla 100 U + Dula on 15,2 %). iGlaLixi decreased a total cost (direct and non-direct) better than Exe, Dula and Lira (on 19,9, 9,3 и 45,2 % accordingly). …”
Get full text

Pharmacoeconomic analysis by the cost-minimization method of fluconazole drugs recommended for use in candidiosis by O. V. Tkachova, L. V. Iakovlieva, T. I. Sheptak

“…Based on the results obtained, using the pharmacoeconomic method of «cost minimization», the least costly drugs were selected for the course of treatment with fluconazole. …”
Get full text

PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT by A. V. Rudakova

Get full text

Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure by S. K. Zyryanov, E. A. Ushkalova

“…Aim. Pharmacoeconomic comparison of medication management strategies (valsartan+ sacubitril) for patients with heart failure (HF), stabilized after an episode of acute decompensated heart failure (ADHF).Material and methods. …”
Get full text

Editorial: Challenges of pharmacoeconomics in global health arena—Contemporary momentum in the early 2020s by Mihajlo Jakovljevic, Mihajlo Jakovljevic, Mihajlo Jakovljevic, Nick Verhaeghe, Nick Verhaeghe, Kyriakos Souliotis, Kristijan Krstic

Subjects: “…pharmacoeconomics…”
Get full text

Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China by Li Zeng, Li Zeng, Huihui Chen, Huihui Chen, Heng Xiang, Mengru Zeng, Mengru Zeng, Mi Zhou, Mi Zhou, Chongqing Tan, Hong Liu, Hong Liu, Guochun Chen, Guochun Chen, Guochun Chen

Subjects: Get full text

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia by R. I. Yagudina, I. Yu. Zinchuk

Subjects: “…pharmacoeconomic analysis…”
Get full text